Hikma Pharmaceuticals PLC

LSE:HIK Stock Report

Market Cap: UK£4.4b

Hikma Pharmaceuticals Valuation

Is HIK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HIK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HIK (£19.84) is trading below our estimate of fair value (£40.16)

Significantly Below Fair Value: HIK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HIK?

Key metric: As HIK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HIK. This is calculated by dividing HIK's market cap by their current earnings.
What is HIK's PE Ratio?
PE Ratio19.3x
EarningsUS$285.00m
Market CapUS$5.51b

Price to Earnings Ratio vs Peers

How does HIK's PE Ratio compare to its peers?

The above table shows the PE ratio for HIK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.4x
GSK GSK
21.7x23.2%UK£54.4b
ANCR Animalcare Group
31.8x5.3%UK£147.3m
AZN AstraZeneca
31.1x18.2%UK£161.4b
EAH ECO Animal Health Group
73.1x39.2%UK£48.1m
HIK Hikma Pharmaceuticals
19.3x12.2%UK£4.4b

Price-To-Earnings vs Peers: HIK is good value based on its Price-To-Earnings Ratio (19.3x) compared to the peer average (39.4x).

Price to Earnings Ratio vs Industry

How does HIK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
HIK 19.3xIndustry Avg. 19.4xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HIK is good value based on its Price-To-Earnings Ratio (19.3x) compared to the European Pharmaceuticals industry average (19.6x).

Price to Earnings Ratio vs Fair Ratio

What is HIK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HIK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.3x
Fair PE Ratio24.2x

Price-To-Earnings vs Fair Ratio: HIK is good value based on its Price-To-Earnings Ratio (19.3x) compared to the estimated Fair Price-To-Earnings Ratio (24.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HIK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£19.84
UK£23.67
+19.3%
12.4%UK£30.85UK£19.98n/a10
Dec ’25UK£19.24
UK£23.39
+21.6%
12.2%UK£30.57UK£20.13n/a10
Nov ’25UK£18.73
UK£23.14
+23.5%
8.7%UK£27.21UK£19.77n/a10
Oct ’25UK£19.11
UK£22.88
+19.7%
10.7%UK£27.85UK£19.23n/a11
Sep ’25UK£19.83
UK£23.22
+17.1%
11.6%UK£28.77UK£19.87n/a11
Aug ’25UK£19.00
UK£22.28
+17.3%
13.2%UK£27.82UK£18.39n/a11
Jul ’25UK£18.67
UK£22.89
+22.6%
13.4%UK£28.64UK£18.93n/a11
Jun ’25UK£19.30
UK£22.94
+18.8%
13.3%UK£28.24UK£18.85n/a11
May ’25UK£19.35
UK£22.82
+17.9%
13.3%UK£28.13UK£18.70n/a11
Apr ’25UK£19.19
UK£22.95
+19.6%
12.6%UK£27.77UK£18.68n/a11
Mar ’25UK£19.34
UK£22.68
+17.3%
12.1%UK£27.53UK£18.63n/a11
Feb ’25UK£19.12
UK£21.98
+15.0%
12.3%UK£26.37UK£18.52n/a11
Jan ’25UK£17.89
UK£22.01
+23.0%
12.1%UK£26.39UK£18.53n/a11
Dec ’24UK£17.58
UK£22.96
+30.6%
11.8%UK£27.27UK£19.16UK£19.2411
Nov ’24UK£19.20
UK£23.83
+24.1%
10.6%UK£28.85UK£20.02UK£18.7311
Oct ’24UK£20.88
UK£24.02
+15.0%
10.5%UK£28.67UK£19.89UK£19.1111
Sep ’24UK£21.73
UK£22.69
+4.4%
11.5%UK£27.50UK£18.50UK£19.8312
Aug ’24UK£21.05
UK£20.86
-0.9%
13.1%UK£26.97UK£17.12UK£19.0012
Jul ’24UK£18.91
UK£20.88
+10.5%
14.0%UK£27.22UK£16.80UK£18.6712
Jun ’24UK£17.92
UK£20.82
+16.2%
14.9%UK£27.77UK£17.13UK£19.3011
May ’24UK£18.41
UK£20.21
+9.8%
15.8%UK£27.68UK£16.75UK£19.3511
Apr ’24UK£16.75
UK£20.32
+21.3%
15.1%UK£27.29UK£16.76UK£19.1911
Mar ’24UK£17.39
UK£20.26
+16.6%
15.1%UK£27.51UK£16.90UK£19.3412
Feb ’24UK£16.93
UK£19.42
+14.8%
17.4%UK£27.18UK£14.23UK£19.1212
Jan ’24UK£15.52
UK£18.75
+20.8%
21.3%UK£27.45UK£12.72UK£17.8912
Dec ’23UK£15.42
UK£19.37
+25.6%
24.9%UK£27.51UK£12.75UK£17.5811

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 23:48
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hikma Pharmaceuticals PLC is covered by 37 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
Simon MatherBarclays
Emily FieldBarclays